Related Experiment Video

Updated: Jun 25, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.9K

Antibiotics for the Secondary Prevention of Coronary Heart Disease

M Mansoor, O Hamer, E Walker

    British Journal of Cardiac Nursing
    |May 30, 2024
    PubMed

    Insights

    Antibiotics may offer secondary prevention for coronary heart disease by reducing inflammation and preventing cardiovascular events. This review assesses the risks associated with using antibiotics for this purpose in patients with coronary heart disease.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Inflammation research

    Background:

    • Coronary heart disease (CHD) affects 200 million globally, a leading cause of death.
    • CHD patients face higher risks of stroke, myocardial infarction, and cardiovascular death.
    • Inflammation and plaque buildup are central to CHD pathophysiology.

    Purpose of the Study:

    • To critically appraise a systematic review.
    • To assess the risks of using antibiotics for secondary prevention in CHD.
    • To evaluate the potential of antibiotics in reducing cardiovascular events.

    Main Methods:

    • Systematic review appraisal.
    • Analysis of antibiotic anti-inflammatory properties.
    • Evaluation of evidence on secondary prevention of CHD.

    Main Results:

    • Antibiotics possess anti-inflammatory and anti-oxidative properties.
    • Theoretical benefit: reduced inflammation may prevent cardiovascular events.
    • Systematic review assessed risks of antibiotic use in secondary CHD prevention.

    Conclusions:

    • Further research is needed to confirm the efficacy and safety of antibiotics for secondary CHD prevention.
    • Antibiotics may hold potential in reducing CHD-related mortality and morbidity.
    • Understanding the risks is crucial for clinical application.

    Keywords:
    AntibioticsCoronary heart diseaseCritical appraisalDrug therapyRandomised control trialSystematic review

    More Related Videos

    A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

    A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

    Published on: May 14, 2013

    25.5K
    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations11:15

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

    Published on: July 24, 2021

    4.6K

    Related Concept Videos

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    489
    Combined Effects of Drugs: Synergism01:27

    Combined Effects of Drugs: Synergism

    Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
    Such synergistic combinations...
    3.8K
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    519
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    647
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
    573
    Peptic Ulcer Disease IV: Management01:26

    Peptic Ulcer Disease IV: Management

    Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
    The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
    Pharmacological management
    The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
    87